Next Article in Journal
Withaferin A Rescues Brain Network Dysfunction and Cognitive Deficits in a Mouse Model of Alzheimer’s Disease
Previous Article in Journal
Design and Synthesis of Pyridine-Based Pyrrolo[2,3-d]pyrimidine Analogs as CSF1R Inhibitors: Molecular Hybridization and Scaffold Hopping Approach
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Lin et al. Huafengdan Inhibits Glioblastoma Cell Growth and Mobility by Acting on PLAU and CAV1 Targets. Pharmaceuticals 2025, 18, 428

1
Key Laboratory of Human Brain Bank for Functions and Diseases, Department of Education of Guizhou Province, College of Basic Medical, Guizhou Medical University, Guiyang 561113, China
2
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 550014, China
3
Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
4
Guizhou Wansheng Pharmaceutical Co., Ltd., Zunyi 563005, China
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(6), 815; https://doi.org/10.3390/ph18060815
Submission received: 13 May 2025 / Accepted: 21 May 2025 / Published: 29 May 2025

Error in Figure 1

In the original publication [1], there was a mistake in Figure 1f as published. During a post-publication review, we identified an inadvertent error in the Western blot panels of Cyclin A2 and GAPDH in Figure 1f. Specifically, the lanes for Cyclin A2 and GAPDH in the U87 cell line were mistakenly labeled as originating from the A172 cell line, and vice versa. This error occurred during figure assembly and does not affect the experimental results, statistical analysis, or conclusions of the study. The corrected Figure 1 appears below. We state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Pharmaceuticals 18 00815 i001

Reference

  1. Lin, D.; Yu, W.; Yu, J.; Cheng, S.; Song, Y.; Wan, X.; Xu, Y.; Luo, H.; Sun, B. Huafengdan Inhibits Glioblastoma Cell Growth and Mobility by Acting on PLAU and CAV1 Targets. Pharmaceuticals 2025, 18, 428. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lin, D.; Yu, W.; Yu, J.; Cheng, S.; Song, Y.; Wan, X.; Xu, Y.; Luo, H.; Sun, B. Correction: Lin et al. Huafengdan Inhibits Glioblastoma Cell Growth and Mobility by Acting on PLAU and CAV1 Targets. Pharmaceuticals 2025, 18, 428. Pharmaceuticals 2025, 18, 815. https://doi.org/10.3390/ph18060815

AMA Style

Lin D, Yu W, Yu J, Cheng S, Song Y, Wan X, Xu Y, Luo H, Sun B. Correction: Lin et al. Huafengdan Inhibits Glioblastoma Cell Growth and Mobility by Acting on PLAU and CAV1 Targets. Pharmaceuticals 2025, 18, 428. Pharmaceuticals. 2025; 18(6):815. https://doi.org/10.3390/ph18060815

Chicago/Turabian Style

Lin, Dengxiao, Wenfeng Yu, Jia Yu, Sha Cheng, Yu Song, Xiaoqing Wan, Yingjiang Xu, Heng Luo, and Baofei Sun. 2025. "Correction: Lin et al. Huafengdan Inhibits Glioblastoma Cell Growth and Mobility by Acting on PLAU and CAV1 Targets. Pharmaceuticals 2025, 18, 428" Pharmaceuticals 18, no. 6: 815. https://doi.org/10.3390/ph18060815

APA Style

Lin, D., Yu, W., Yu, J., Cheng, S., Song, Y., Wan, X., Xu, Y., Luo, H., & Sun, B. (2025). Correction: Lin et al. Huafengdan Inhibits Glioblastoma Cell Growth and Mobility by Acting on PLAU and CAV1 Targets. Pharmaceuticals 2025, 18, 428. Pharmaceuticals, 18(6), 815. https://doi.org/10.3390/ph18060815

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop